Preparations for medical, dental, or toilet purposes (A61K)

A   Human necessities(304962)
A61K              Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l)(49752)
A61K7 - (2074)
A61K37 - (206)
A61K43 - (6)
Combination for acne treatment and method of its application // 2614392
FIELD: pharmacy.SUBSTANCE: combination for acne treatment, comprising an aqueous Gynura Procumbens leaf extract, and means containing non-activated platelets and white blood cells in their own blood plasma. A method of acne treatment by application of the above combination.EFFECT: combination and treatment method are characterized by high efficiency in acne treatment.2 cl, 2 dwg

Immunity-inducing means // 2614386
FIELD: biotechnology.SUBSTANCE: invention refers to production of means containing at least one polypeptide selected from SEQ ID NO: 4, 2, 8, 10 and 12, and/or recombinant vector(s), comprising polynucleotide(s) encoding at least one polypeptide, as the active ingredient(s), and can be used in medicine. The resulting means is used for efficient induction of T-cell immunity against malignancies expressing KATNAL1.EFFECT: invention allows to obtain antigen-presenting cells presenting the polypeptide obtained from KATNAL1, and to effectively induce cytotoxic cells against KATNAL1, which is efficient as a therapeutic agent against malignant neoplasms expressing KATNAL1.7 cl, 3 dwg, 3 ex

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex

Agent with antitumor activity based on arabinogalactan nanocomposites with selenium and methods for prepariation of such nanobiocomposites // 2614363
FIELD: pharmacy.SUBSTANCE: method of agent production includes interation of raw arabinogalactan and selenium dioxide or selenious acid salt in a solvent followed by precipitation in ethanol or acetone, or other organic solvent capable of mixing with water. The peculiarity of this method is that the process is carried out at the temperature of 20-25°C, stable selenium nanoparticles size is 0.5-250 nm, and raw arabinogalactan or arabinogalactan specially purified from phenolic impurities is used as the raw materila, while water or dimethylsulfoxide, or formamide are used as solvents.EFFECT: soluble stable nanocomposites providing antitumor activity, in dry form.3 cl, 7 dwg, 11 ex
ethod for preparation of collagen product // 2614273
FIELD: pharmacy.SUBSTANCE: invention refers to processing and cosmetics industris, namely to a method for production of a collagen product with the following characteristics: reception of skins of freshwater fish such as silver carp, carp, grass carp, mirror carp, manual or machine cleaning from scale, muscle tissue, fins and mechanical impurities, washing for 30 minutes in drum type machines with a solution of soap and then in water - to remove residual soap, the rinsed skins are subjected to peroxide and alkaline treatment, for which they are poured with a mixture of hydrogen peroxide with mass concentration of 3% and sodium hydroxide with mass concentration of 3 % and kept at 20-25°C for 1.5-2 hours and liquor ratio of 1:4, the treated skins are washed with flowing water at 8-12°C for 10-15 min, then the skins are poured with citric acid solution with mass concentration of 6% and kept for 6 days, the resulting mass is homogenized, packaged in polyethylene and stored at 0…+4°C for° max. 4 months.EFFECT: increase of collagen product quality indicators: increase in collagen output, improved organoleptic properties, reduced complexity and cost by reducing the number of process steps and reagents, intensification of the pre-treatment process and raw materials degreasing.1 tbl, 2 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Alpha-v beta-8-binding antibodies // 2614252
FIELD: pharmacy.SUBSTANCE: antibodies with high affinity for β8-subunit αvβ8 proposed. Pharmaceutical composition comprising such antibodies, and methods of their application are also described. The proposed group of inventions can be used in medicine.EFFECT: improved antibody properties.23 cl, 14 dwg, 19 ex

Osteotropic radiopharmaceuticals for pet imaging // 2614235
FIELD: medicine.SUBSTANCE: invention relates to the field of nuclear medicine, namely to radiopharmaceuticals (RF) for metastatic bone lesions imaging using the positron emission tomography (PET) techniques and radiation therapy planning. This goal is achieved by application of a composition representing a solution containing gallium-68 in the form of a complex with oxa-bis (ethylene-nitrile)tetrametylene-phosphonic acid and sodium chloride, sodium hydroxide and a phosphate buffer containing sodium phosphate and sodium hydrogen phosphate, as the preparation for PET imaging of metastatic bone lesions and radiation therapy planning. Preparation is obtained from a lyophilized composition at the room temperature during 1-2 minutes, radiochemical purity of the preparation is more than 90%, pH range is from 4.5 to 8.0, maximum accumulation of drug in a pathological bone shall be reached 1.5 hours after introduction, and is 40-45% of the introduced activity, differential callus/blood accumulation factor is more than 10, accumulation of the drug in blood is less than 0.30%/year.EFFECT: invention expands the number of nuclear medicine devices, particularly for metastatic bone lesions imaging using the positron emission tomography (PET) techniques and radiation therapy planning.3 dwg, 4 ex, 1 tbl
Pharmaceutical composition based on 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine as anti-tumor agent // 2614234
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and includes pharmaceutical composition, which is solution of pharmaceutically acceptable substance 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine of formula (I) and D-mannitol in water. Composition is used for therapy of malignant tumors in human or animal.EFFECT: technical result is obtaining stable, long-term stored solution of Substance 1.1 cl

ethod of treating chronic elbow and prepatellar brusitis // 2614207
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to traumatology-orthopedics and surgery, and can be applied for treatment of chronic elbow and prepatellar brusitis. For this purpose puncture of bursa, its content aspiration, introduction of medication in its cavity, drainage of bursa with constant active aspiration are realised. As medication 2 ml of heparin 10000 IU are introduced in bursa cavity. After 24 hours aspiration of content is carried out and 2 ml of heparin 10000 IU and 10 mg of trypsin are introduced. 3 hours after this vacuum system of active aspiration is placed in bursa cavity. Further, in a day removal of aspiration liquid from system is realised in the process of bandaging. System of active aspiration is applied until exudate extraction from bursa stops.EFFECT: method ensures improvement of treatment effects as a result of reduction of pain reaction to medicinal procedure, reduction of quantity of recurrences as a result of active influence on synovial envelope of bursa, thorough evacuation of its content and activation of regeneration processes.1 dwg, 2 ex
ethod for myocardial revascularization in case of coronary artery disease // 2614196
FIELD: medicine.SUBSTANCE: combined effect on the myocardium is provided, including laser treatment and intramyocardial administration of autologous bone marrow stem cells (ABMSC). Through channels in the left ventricular wall in the myocardial ischemia area or areas are performed, with diameter of 0.3-1.0 mm and frequency of one channel per 1 cm2 of the left ventricle wall. Each channel is perpendicular to the left ventricle outer wall surface in the channel forming area. Channels are formed using the impact of CO2 laser, with a power of 800-1000 W and pulse duration of 20-50 ms. The pulse duration is chosen sufficient to form a channel by one pulse within the refractory period of the cardiac cycle. Then, 200 l of a solution containing 8.3 million of ABMSC is administered around each channel along its entire length using one injection. The needle is directed in the avascular zone at a distance of 1-2 mm from the outer channel wall. ABMSC is introduced when extracting the needle.EFFECT: reduction of intervention trauma, while maintaining its efficiency, reducing the volume of fluid injected with ABMSC, as well as application of one pulse to form a through channel in the myocardium, prevention of intraoperative complications and induced arrhythmia due to the laser pulse impact by forming channels in the myocardium within the refractory period of the cardiac cycle.1 ex

Reduction of level of lactate and increasing of production of polypeptide by inhibiting expression of lactate dehydrogenase and pyruvate dehydrogenase kinase // 2614125
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and concerns method of reducing lactate production in mammalian cells, method of silencing or reduction in mammal cell of transcription of lactate dehydrogenase (LDH) and pyruvate dehydrogenase kinase (PDHK), method of producing mammal cells, which exhibits low production of lactate in culture, vector containing first heterologous nucleotide sequence coding small interfering RNA (siRNA), specific for lactate dehydrogenase, and second heterologous nucleotide sequence coding siRNA specific for pyruvate dehydrogenase kinase, each of which is connected with its promoter.EFFECT: presented inventions allow reducing in cultured cells production of lactate and increasing of production of heterologous polypeptide.40 cl, 6 dwg
ethod for producing a complex shigellosis drug // 2614123
FIELD: pharmacy.SUBSTANCE: method involves mixing of equal weight amounts of modified lipopolysaccharide Shigella flexneri 2a and exopolysaccharide Shigella sonnei in the buffered solution of the following composition: 0.2 M NaCl, 0.05 M Tris, 0.25% sodium deoxycholate, pH 8.3, at 80°C, followed by dialysis against the same buffered solution without sodium deoxycholate and then against deionized water followed by lyophilization. In this case the modified lipopolysaccharide Shigella flexneri 2a lipid A is partially O-deacylated. The said modified lipopolysaccharide Shigella flexneri 2a is obtained as a result of selective alkaline hydrolysis of the original lipopolysaccharide Shigella flexneri 2a.EFFECT: invention provides a drug with low toxicity, high efficiency and bimodal specificity.2 dwg, 3 tbl, 5 ex

ethod of producing human immunoglobulin // 2614119
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Group of inventions is described, which involves method of producing human immunoglobulin and preparation of human immunoglobulin, obtained using said method. Method includes stage of dissolving of Cohn component I+II+III or Cohn component II+III in water for injections; deposition with caprylic acid or caprylate; first stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (2), to 5.2, cleaning by anion-exchange chromatography and obtaining eluating solution; deposition of IgM, including control of conductivity of eluating solution obtained at step (3), up to 500–1,000 µS/cm by means of water and further bringing pH to 6.0–7.3,with subsequent settling for 1–2 hours, filtration and filtrate collection; second stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (4) to 5.6, subsequent purification by anion-exchange chromatography and collection of eluating solution; production of human immunoglobulin by dialysis of eluating solution obtained at step (5), by ultrafiltration, obtaining pharmaceutical form and inactivation of viruses.EFFECT: invention extends range of methods for producing human immunoglobulin.9 cl, 2 dwg, 3 tbl, 2 ex

Recombinant somatostatin-containing protein, method for production, injecting drug to increase meat and dairy efficiency of agricultural animals, and method for drug application // 2614115
FIELD: biotechnology.SUBSTANCE: recombinant immunogenic protein comprising somatostatin and glucosan-binding domain. The method for protein production on glucosan is presented, which includes protein binding to the glucosan-containing sorbent due to affinity interaction, followed by washing of unbound bacterial proteins and isolation of the desired product. An injected preparation based on the protein is also described. A method for farm animals muscle mass and milk production increase is described comprising conducting twice subcutaneous or intramuscular drug injection. The invention allows to obtain a recombinant somatostatin-containing immunologically active protein, easy to purify and having sufficient immunogenicity against somatostatin.EFFECT: invention can be used to increase meat and milk production of farm animals by induction of synthesis of specific antibodies to somatostatin, blocking of its action, and as a consequence, anabolic processes enhancement in animals.4 cl, 3 tbl

Bacteriophages, phage peptides and methods for application thereof // 2614114
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Described is bacteriophage F510/08, comprising genome, which contains nucleic acid sequence SEQ ID NO: 4. Bacteriophage shows activity upon Pseudomonas aeruginosa. Invention also describes versions of pharmaceutical composition containing such bacteriophage, and methods of therapy for treatment and prevention of bacterial infection.EFFECT: presented group of inventions can be applied in medicine.23 cl, 327 dwg, 7 tbl, 7 ex
Novel efficient inhibitor of kinase 4, associated with interleukin-1 (irak4) // 2613973
FIELD: chemistry.SUBSTANCE: invention relates to a compound of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate. Compound according to invention is intended for preparing a pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase. Pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase, is characterized by that it contains a therapeutically effective amount of compound according to invention and pharmaceutically acceptable carrier, solvent and/or filler. Pathological condition associated with aberrant activity of IRAK4 kinase is an immune inflammatory disease or oncological disease.EFFECT: technical result is production of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate as a selective IRAK4 kinase inhibitor.13 cl, 10 dwg, 2 tbl
Processed silicon oxides and metal silicates for improved cleaning in dental care means // 2613924
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to materials based on treated silicon dioxide, as well as to methods for manufacture of such materials. The method for material preparation based on thermally treated silicon dioxide comprises thermal treatment of the material based on precipitated metal-containing silicon dioxide wherein the metal has a Mohs hardness value of at least 5.5 in the form of oxide. The metal material comprises aluminum or tin. Thermal processing involves heating of material based on precipitated silicon dioxide at a temperature of 400°C during about 8 hours. The resulting material is characterized by loss on ignition of less than 3% by weight at 900°C. Einlehner attrition value is 90 - 450% greater than the Einlehner attrition value for material based on precipitated silicon dioxide.EFFECT: invention provides an effective means for teeth cleaning.24 cl, 4 tbl, 2 ex

Conjugated protein-active agents and methods of their production // 2613906
FIELD: pharmacy.SUBSTANCE: conjugated protein active agent has an amino acid motif which can be recognized via isoprenoid transferase, wherein the active agent is covalently bound via at least one linker with izosubstrate, where the izosubstrat contains at least one isoprene unit and is a recognizable isoprenoid transferase, which is attached to a cysteine residue of the amino acid motif. The invention also relates to a composition comprising conjugates, and to methods for preparing conjugates and compositions.EFFECT: use of the conjugates for the delivery of the active agent into target cells with a high selectivity.16 cl, 27 dwg, 5 ex

Liquid composition of long-acting alpha interferon conjugate // 2613905
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to the field of pharmacy and medicine and relates to a liquid composition (options), in which the long-acting INF conjugateα and the immunoglobulin Fc-fragment are covalently linked by a non-peptidic polymer, and includes a stabilizer with a buffer, sugar alcohol, a nonionic surfactant and an isotonic agent; at that, it does not contain human serum albumin and other potential factors harmful for the organism. The inventive method for liquid composition production and a stabilizer are also stated.EFFECT: group of inventions provides excellent storage stability of long-acting INF conjugatesα with improved durability and stability in vivo, can be safely stored for a long period of time.17 cl, 1 dwg, 6 ex, 12 tbl
Pharmaceutical composition of glibenclamide in form of solution for injections and method for its production // 2613902
FIELD: pharmacology.SUBSTANCE: group of inventions relates to a pharmaceutical composition in the form of a solution for injections, containing glibenclamide as an active ingredient in an amount of 0.0004-0.004 g per ml of the solution, and hydroxyethylstarch 200/0.5 in an amount of 0.025-0.075 g per ml of solution and water for injections (the rest) as auxiliaries, as well as to the method for obtaining such a pharmaceutical composition, according to which hydroxyethylstarch 200/0.5 is added in water for injections preheated to 85-90°C and stirred until complete dissolution, glibenclamide powder is added and stirred at 75-85°C until completely dissolution, water for injections is added to obtain the final solution volume and stirred again; the resulting solution is maintained for 35-40 minutes at 75-85°C, cooled to 20-30°C, sterilised by the method of filtration through filters with the pore diameter of 0.22 mcm and packaged in ampoules, which are additionally sterilized for 8 minutes at a temperature of 120°C.EFFECT: creation of a new preparation form of glibenclamide, characterized by low formation of undesirable impurities during storage.2 cl, 3 ex
Production method of brucellar monospecific serum anti-melitensis // 2613901
FIELD: veterinary medicine.SUBSTANCE: provide the immunizations of rabbits with a single dose of B. melitensis strain. The rabbits immunization is carried out subdermally in the dewlap area with suspension of 1 ml volume, which contains:. 200 million MK inactivated culture of B. melitensis strain 16M with adjuvant MONTANIDE™ ISA 61 VG. At the 14th-16th day the trial blood collecting is conducted, and at the 21st-45th day the three-time blood collecting is carried out and at the 60th day it is dehematized. The serum is obtained and inactivated at 60-65°C during 1-1.5 hours. The cross adsorption with bacteriological weight of B. abortus 544 strain is carried out, obtained by culture growing within 70-72 hours. Centrifuge with cooling the residue during 24-26 hours, adding to the residue the physiological solution for obtaining the bacterial weight in the amount of 3.5-3.7×109 pfu per 10 ml of serum. Further incubate at 37°C for 2 hours and restore the serum by centrifugation with further preserving and packaging.EFFECT: utilisation of this method allows the use the inactivated Brucella culture to produce a monospecific serum, and take blood from each of the rabbits for at least four-times, increasing the amount of the resulting serum.2 ex, 8 tbl
Pharmaceutical composition comprising fimasartan and hydrochlorothiazide // 2613900
FIELD: medicine, pharmacy.SUBSTANCE: pharmaceutical composition comprises 132.02 mg of potassium fimasartan trihydrate, 12.5 mg of hydrochlorothiazide and a binder, which binding solution has a viscosity from 20 mPa·s to 650 mPa·s. The binder includes at least one substance selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone. A method for preparation of a pharmaceutical composition by wet granulation and a pill obtained in this manner are also described. This composition is characterized by a standard deviation (RSD) of 4.0% or less in the content uniformity test of the active ingredients. The uncoated pill has a crush strength of 7 Kp or more as per the invention.EFFECT: invention refers to a pharmaceutical composition in the form of pill for hypertension treatment.9 cl, 12 tbl, 11 ex

Concentrate // 2613894
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to set of dry concentrate for producing medical solution, application of this set for producing medical solution, as well as to method of producing medical solution based on set of dry concentrate. Components are located in three or more compartments, first compartment contains calcium carbonate and anhydrous calcium chloride with physiologically acceptable acid, second compartment contains osmotic component, and third compartment contains buffer component.EFFECT: invention implementation allows to reduce hygroscopicity of electrolyte components of concentrate, as well as enhance their stability during storage.25 cl, 8 tbl, 6 ex, 5 dwg
ethod for involutional changes correction in lateral brow areas // 2613893
FIELD: medicine.SUBSTANCE: method comprises correction performed in several stages, with the first stage of botulinum toxin injection, the second correction stage takes place in 10-15 days by injection of filler based on hyaluronic acid. Botulinum toxin is injected intramuscularly is carried out in four points on the boundary of the upper and middle third of the forehead, and in two points located on the caudal eyebrows, with a dosage of 2 units per each point. The second stage includes marking of zones deficient in soft tissue augmentation in the lateral eyebrow areas and marking of vascular pattern in these areas for introduction of filler based on hyaluronic acid. Then the cannula access point is selected for each specified area near the outer corner of the eye, 1 cm apart from the lateral bone edge of the orbit, avoiding its intersection with the vascular pattern, and marked. Then the cannula passage vectors are marked, that diverge as beams from the access point in the direction of zones deficient in soft tissue augmentation, and then the filler is injected using a linear retrograde technique by means of a 25G cannula, not more than 0.1 ml of filler per cannula passage vector. Not more than 0.3 ml of filler is used for each lateral brow area.EFFECT: use of the invention allows to improve the efficiency of correction of age-related changes of the lateral brow area due to complex effects.4 dwg, 1 ex

Testosterone compositions // 2613891
FIELD: medicine.SUBSTANCE: transdermal or transmucosal composition for treatment of testicular failure due to testicles abnormalities, Klinefelter syndrome, congenital abnormalities of sex chromosomes X and Y, retained testis, hemochromatosis, high levels of iron in blood, testicular trauma, previous hernia surgery, cancer treatment, normal ageing; secondary hypogonadism due to pituitary defects associated with brain that regulates hormone secretion, weakened testicular function, inflammatory diseases and application of drugs for treatment of psychiatric disorders and gastroesophageal reflux disease, ageing; and infertility, fatigue, loss of energy, depressed mood, regression of secondary sexual characteristics of male subjects, contains: 2 wt % of testosterone, C2-C4 alkanol, approx. 20 wt % of polyalcohol and monoalkyl ester of diethylene glycol.EFFECT: composition has a good skin tolerability.34 cl, 13 dwg, 10 tbl, 8 ex
ethod for preoperative treatment of patients with locally advanced cervical cancer at t1b2-t2b stage // 2613888
FIELD: medicine.SUBSTANCE: invention can be used to pre-treat T1b2-T2b locally advanced cervical cancer (CC). The method comprises superselective chemoembolization of cervical arteries. Then the ascending branches of uterine arteries are cut off from the blood flow by their redistributive embolization using a hemostatic sponge. Then uterine artery chemoembolization is performed, when the superselective chemoembolization of cervical arterial and chemoembolization of uterine arteries uses 25 mg of drug-saturable HepaSpheres microspheres with dry particle size of 50-100 microns, which is saturated with 100 mg of oxaliplatin diluted in a non-ionic contrast agent.EFFECT: use of the invention can improve the efficiency of drug-saturable microspheres delivery to the cervical tumor, which reduces the risk of damage to adjacent organs and tissues and prevents the development of ischemia and necrosis.4 dwg, 2 ex
Split-resistant low molecular cross-linked hyaluronate // 2613887
FIELD: biotechnology.SUBSTANCE: hydrogel is formed by sodium hyaluronate substrate with an average molecular weight of 50,000 to 100,000 Da, cross-linked with diglycidyl ether of 1,4-butanediol, which is obtained by a method comprising interaction of 8-40% solution of sodium hyaluronate with an average molecular weight of 50,000 to 100,000 Da in 0.75-1.5% aqueous solution of sodium hydroxide with the diglycidyl ether 1,4-butanediol volume of 180 to 500 moles per one mole of sodium hyaluronate.EFFECT: product has a high resistance to enzymatic degradation.14 cl, 15 dwg, 5 tbl, 14 ex
ethod for cancer adoptive immunotherapy // 2613884
FIELD: medicine.SUBSTANCE: tumor cells culture is contacted with natural killer cells and cytotoxic T-cells isolated from peripheral blood using 8 CD Micro Beads, human CD 56 and Micro Beads, human reagents. They are saturated with deuterium by incubation and culturing in the presence of interleukin-2 at a concentration of 10,000 IU/ml and heavy water concentration 7.7% at 37°C for 72 hours. Application of this method allows to increase the cytotoxic activity of lymphocytes responsible for tumor immunity, by deuterium saturation resulting in release of more stable oxidizing agents in an antitumor response.EFFECT: increased cytotoxic activity of lymphocytes in vitro.

Process of getting rosemary nanocapsules in sodium alginate // 2613883
FIELD: nanotechnology.SUBSTANCE: for shells of nanocapsules sodium alginate is used, and the rosemary powder is slowly added to a suspension of sodium alginate in petroleum ether in the presence of 0.01 g E472c as a surfactant, and then stirred at 1000 r/min and the ethyl acetate is poured, the resulting suspension is filtered and dried at room temperature, wherein the weight ratio of core: shell in nanocapsules is 1:1 or 1:3.EFFECT: simplification and acceleration of the process of producing the nanocapsules of rosemary, as well as increase their yield by weight.1 dwg, 3 ex
ethod for producing dry rosehip extract nanocapsules // 2613881
FIELD: nanotechnology.SUBSTANCE: method for producing nanocapsules of dried rosehip extract, wherein as the shell of the nanocapsules the Konjac Root Powder is used, dry rosehip extract is dispersed in a Konjac Root Powder butanol in the presence of 0.01 g E472s as surfactant while stirring 1300 rev/min, then 5 ml of chloroform, after which the precipitate was filtered off and dried at room temperature, wherein the ratio of dry rosehip extract to Konjac Root Powder is 1:1, 1:3 or 5:1.EFFECT: way to simplify and accelerate the process of producing the nanocapsules, to increase the yield by weight.4 ex
3-methyl-1,2,4-triazole-5-thioacetate (s) -2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning // 2613875
FIELD: pharmacy.SUBSTANCE: 3-methyl-1,2,4-triazole-5-thioacetate (s)-2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning is proposed.EFFECT: highly effective prevention of central nervous system vital functions in case of preventive administration, adjustment of neurotoxic lesions in case of severe forms of acute ethanol poisoning, which in turn allows earlier restoration of the central nervous system vital functions and mortality reduction in case of acute ethanol poisoning.1 tbl

ethod for production "ks" swine fever vaccine nanocapsules in sodium alginate // 2613795
FIELD: biotechnology.SUBSTANCE: method includes dilution of 55 mg of "KS" vaccine were dissolved in 3 ml of petroleum ether and dispersed into a sodium alginate suspension in petroleum ether containing 550 mg of this polymer in the presence of 60 mg of E472s preparation as surfactant while stirring at 1000 rpm, then 5 ml of ethyl acetate is added, the precipitate is filtered and dried at room temperature.EFFECT: simplification and acceleration of "KS" vaccine nanocapsules production process, increasing their output by weight.1 dwg, 1 tbl, 3 ex
ethod for spinocerebellar ataxia treatment // 2613765
FIELD: medicine.SUBSTANCE: method involves one-time daily oral administration of L-cysteine, at that, the course of treatment is not less than 3 months, and the received single dose is 500 mg.EFFECT: use of the invention improves the efficiency of treatment of spinocerebellar ataxia type 1 due to neurodegeneration process regression.3 ex

ethod for praparing nanocapsules of medicinal plants having sedative effect // 2613761
FIELD: pharmacology.SUBSTANCE: invention relates to chemical and pharmaceutical industry, and is a method for preparing nanocapsules of the medicinal plants having a sedative effect, characterized in that the tinctures of valerian, motherwort and anomalous peony are added to the suspension of sodium carboxymethyl cellulose in acetone in the presence of 0.01 g of E472s preparation as a surfactant, while stirring at 1300 rev/min, the prepared suspension is filtered and dried at room temperature, wherein the ratio of core: shell in case of preparing the motherwort tincture nanocapsules is 1:3, 1:1, 5:1 or 1:5, in the case of preparing the valerian tincture nanocapsules is 1:3, 1:1, 5:1, 1:5, in the case of preparing the anomalous peony tincture nanocapsules is 1:3, 1:5.EFFECT: invention allows to simplify and accelerate the method of preparing the nanocapsules and to increase the weight yield.3 dwg, 11 ex
ethod for alternative treatment of insulin-producing pancreas benign tumour // 2613717
FIELD: medicine.SUBSTANCE: for an alternative treatment of insulin-producing pancreas benign tumour, a research of immunoreactive insulin and C-peptide level is conducted. If the parameters exceed their reference values, tumour location is identified, and tumour radiofrequency thermoablation is performed with hormonal parameters monitoring. Preliminary medical therapy by 0.1 mg of octreotide injected subcutaneously 1 time per day is performed for 3 days prior to radiofrequency thermoablation. Radiofrequency thermoablation is carried out in two stages. At the first stage, radiofrequency thermoablation of the central part of the localized tumour is performed for 3 minutes at a temperature of 85-100 degrees Celsius and power 70-90 Wt under intraoperative ultrasonography supervision. The exposure is carried out at RF electrode conductors introduced to a depth of 0.4-0.7 cm . At the second stage, repeated RF thermoablation of the entire tumour within the boundaries of its detected contouris is performed with the same modes of time, temperature and power.EFFECT: persistent therapeutic effect due to minimally invasive organ-saving and almost complete destruction of tumour at low risk of intra- and postoperative complications, normalization of hormonal status.5 tbl, 5 ex

Ophthalmic composition with high concentration of olopatadine // 2613715
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and is intended for treatment of allergic eye conjunctivitis. Ophthalmic composition for treatment of allergic eye conjunctivitis comprises at least 0.67% wt/vol, but not more than 1.0% wt/vol of olopatadine which is dissolved in the solution. The composition is placed in an eye drop dispenser for drop application of composition into the eye with droplets size of at least 18 mcl, but not more than 45 mcl. The composition has a pH from 5.5 to 8.0. Additionally, the composition comprises polyethylene glycol, polyvinylpyrrolidone and the cyclodextrin derivative in the stated amounts. Also a method of symptoms of eye allergy symptoms treatment is provided.EFFECT: invention allows more effective reduction of allergic eyenconjunctivitis symptoms, especially the symptoms of late-phase allergic eye conjunctivitis.25 cl, 5 dwg, 20 tbl, 2 ex

Use of mixture of salt and sugar for preparing drug used for treatment of syndrome of vaginal muscle strain or coleitis xerosis in mammal // 2613714
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to gynecology, and can be used for treating or preventing syndrome of vaginal muscle strain or coleitis xerosis in mammal. For that composition is introduced containing sodium chloride and glucose, mixed at ratio of 1:1 to 1:30 (wt/wt).EFFECT: it provides better contractility of vaginal smooth muscles and reduced coleitis xerosis.6 cl, 3 dwg, 5 tbl, 3 ex

Ways of acne treatment // 2613708
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used to treat acne. To do this, plating of B. bifidum №1 suspension in saline solution ( 106 Cfu/ml) prepared from "Bifidumbacterin" with 100: 1 ratio into a sterile thioglycolic environment is performed, then it is incubated at (371±)°C during 48 h, the sterile gauze is impregnated with the resulting broth culture of bifidobacteria and applied on the affected skin for 30 minutes, the procedure is repeated 2 times a day.EFFECT: invention provides reduction in virulence of pathogens and persistent properties of acne due to the action of exometabolites and intact cells of lactic acid bacteria.3 dwg, 1 tbl, 3 ex
Vaccine for protection of ruminant animals against pneumonia caused by pasteurella multocida // 2613672
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary science and is intended for protection of ruminant animals against pneumonia caused by P. Multocida. Disclosed method involves introduction of vaccine containing living attenuated bacteria P. multocida, in upper parts of airway of ruminant animal by intranasal vaccine spraying.EFFECT: disclosed method is highly effective for protection of ruminant animals against pneumonia caused by Pasteurella multocida.5 cl, 5 tbl, 2 ex
Chloride 4-[(1e)-1-(6-chloro-4-oxo-4n-chromen-3-yl)-4-methylpent-1-en-3-yl]morpholine-4-yl, method of producing thereof and its antituberculosis effect // 2613633
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, namely to chloride 4-[(1E)-1-(6-chloro-4-oxo-4H-chromen-3-yl)-4-methylpent-1-en-3-yl]morpholine-4-yl of formula I and method of producing thereof.EFFECT: new heterocyclic compound, may be used as a potential antituberculosis drug.3 cl, 5 dwg, 2 tbl, 2 ex
Ido inhibitors // 2613579
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, in particular, to derivatives of imidazo[5,1-a]isoindole of structure given below, or to a stereoisomer or pharmaceutically acceptable salt thereof, where bond α is a single or double bond; n = 0 or 1; R1: halogen or -OR; R2: -C1-4alkyl-RA or -C2-4alkenyl-R3, if bond α is a single bond; and R2: =C(H)RA, if bond α is a double bond; in which RA: -CN, -C(O)R3, -C(O)OR3, -C(O)N(R3)(RC), -C(ORB)(R3)(RC), -C(NHRB)(R3)(RC), or -C(=N-ORC)R3, where RB: hydrogen, -C(O)R3, -C(O)N(H)R3, -C(O)(CH2)2COOR, -C(O)(CH2)1-4(NR)COOR, -C(O)CH(NH2)(RD), or -P(O)(OR3)2; where RD: methyl or -CH(CH3)2; R3: hydrogen, C1-6alkyl, phenyl, imidazolyl, furanyl, thiazolyl, pyridinyl, C5-6cycloalkyl, C3-8cycloalkenyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, azetidinyl or C6cycloalkylC1alkyl-, where each alkyl, cycloalkyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl and azetidinyl is optionally and independently substituted with one group =R32 and optionally and independently substituted with one or two groups R31; each phenyl, imidazolyl, furanyl, thiazolyl and pyridinyl is optionally substituted with one or two groups R31; where R31: halogen, nitro, C1-6alkyl, -C1-6alkyl-R33, C1-6haloalkyl, -OR, -N(R)2, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)2R, -OC(O)R, -N(R)C(O)R or -N(R)C(O)OR, where R33: -OR; R32: =O, =C(R34)2, =(spiro-C3-8cycloalkyl), or =(spirodioxalanyl), where R34: hydrogen, halogen, C1-6alkyl or -C1alkyl-OR; RC: hydrogen or C1-6alkyl; and R: hydrogen or R10, where R10: C1-6alkyl, phenyl, thiophenyl, C5-6cycloalkyl, pyrrolidinyl, tetrahydropyranyl, phenylC1-6alkyl, heteroarylC1-2alkyl- (where heteroaryl group is a pyridine, pyrimidine or imidazole) or tetrahydropyranC1alkyl, where each of alkyl, phenyl, cycloalkyl and phenylC1-2alkyl optionally substituted with one or two groups, which independently represent a halogen, C1-6alkyl, C1haloalkyl, -OR11, -N(R11)2 or -N(R11)S(O)2R11, where R11: hydrogen or C1-6alkyl. Invention also relates to specific compounds, pharmaceutical composition based on declared imidazo[5,1-a]isoindole and a method of treating indoleamine-2,3-dioxygenase (IDO) mediated immunosuppression.EFFECT: novel derivatives of imidazo[5,1-a]isoindole are obtained, having useful biological properties.42 cl, 1 dwg, 75 ex
ethod of intraoperative hypotension prediction during anesthesia // 2613564
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to anesthesiology. For general anesthesia, 500 mg/kg of esmosol is injected for 1 minute intravenously as a medication. During assessment of the central hemodynamics response, patient's heart rate, mean arterial pressure and left ventricular power index are determined. If the heart rate is 50-100 per minute, both before and after drug administration, mean arterial pressure is 65-135 mmHg both before and after drug administration, and the value of the left ventricular power index after administration of the said formulation reduces by 27% and more compared to the value obtained before administration, intraoperative hypotension, which consists in mean arterial pressure decrease below 60 mm Hg is predicted.EFFECT: invention allows to predict intraoperative hypotension during general anesthesia.2 cl, 2 tbl, 1 dwg, 2 ex

onohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same // 2613555
FIELD: chemistry.SUBSTANCE: invention relates to a crystalline form a fimasartan potassium salt monohydrate, where crystalline form of a fimasartan potassium salt monohydrate is characterised by X-ray powder diffraction spectrum peaks using Cu-Kα radiation in diffraction angles with value 2θ, reduced at 6.67±0.2, 7.62±0.2, 11.03±0.2, 15.32±0.2, 16.49±0.2, 20.12±0.2, 25.65±0.2 and 27.28±0.2. Invention also relates to methods of producing a fimasartan potassium salt monohydrate and to a pharmaceutical composition.EFFECT: technical result is a novel crystalline form of a fimasartan potassium salt monohydrate, which is resistant to moisture and temperature and has same particle size of crystal.23 cl, 6 dwg, 6 tbl, 18 ex
Propenoate betulin derivatives // 2613554
FIELD: pharmacy.SUBSTANCE: invention relates to a compound or a pharmaceutically acceptable salt thereof, having the following structure: The invention also relates to other individual compounds and pharmaceutically acceptable salts thereof, the structural formulas of which are indicated in the claims, a pharmaceutical composition for HIV replication inhibition and to a method for HIV infection treatment.EFFECT: new propenoate betulin derivatives are obtained, that inhibit HIV replication.20 cl, 2 tbl, 35 ex
Composition based on r(-)-praziquantel for treating and preventing helminthiasis in warm-blooded animals // 2613490
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and can be used for treating and preventing helminthiasis in warm-blooded animals, including agricultural and domestic animals, in particular cats and dogs. For this anthelminthic composition is proposed containing as an active agent combination of praziquantel enantiomer (R-praziquantel, R-PZQ), presented in the form of complex with beta-cyclodextrin, and pyrantel pamoat, as well as water and vegetable oil, neutral filler and auxiliary additives, particularly additive with hepatoprotective and GIT microflora recovering action in following proportions (wt%): R-praziquantel 0.1–0.5, pyrantel pamoat 1.0–3.0, beta-cyclodextrin 1.5–5.0, fillers and auxiliary additives 1.2–5.3, vegetable oil 4.0–22.0, water – rest. Proposed water-oil suspension is characterized by wide spectrum of action, storage stability, ease of use, texture and taste, acceptable for animals, and differs from known analogues in higher efficacy of cystocidal action, achieved due to possibility of 2-5-fold reduction of effective dose of R(-)-praziquantel in comparison with conventionally used racemic mixture.EFFECT: invention provides improved consumption by animals, including any kinds of dogs, kittens and puppies, as well as aged and/or debilitated animals.6 cl, 9 tbl, 5 ex
5-fluoro-4-imino-3-(substituted)-3,4-dihydropyrimidin-2-(1h)-one derivatives, composition based thereon and method for controlling fungal diseases // 2613451
FIELD: agriculture.SUBSTANCE: invention relates to agriculture. Fungicidally active compound of formula I: formula I, wherein R1 represents: C1-C6-alkyl, optionally having as substitutes from 1 to 3 radicals R3; C1-C6-alkenyl, optionally having as substitutes from 1 to 3 radicals R3; C3-C6-alkynyl, optionally having as substitutes from 1 to 3 radicals R3; phenyl or benzyl, wherein each phenyl or benzyl can optionally contain as substitutes from 1 to 3 radicals R4, or a system of 5- or 6-member saturated or unsaturated rings, or condensed system consisting of 5- and 6-member rings, or condensed system of 6-6-member rings, each system includes from 1 to 3 heteroatoms, and each ring can optionally contain as substitutes from 1 to 3 radicals R4, -(CHR5) mOR6; -C(=O)R7; -C(=S)R7; -C(=O)OR7; -C(=S)OR7; -S(O)2R7; -(CHR5)mN(R8)R9; -C(=O)N(R8)R9; or -C(=S)N(R8)R9; where m is an integer from 1 to 3; R2 represents: H; or C1-C6-alkyl, optionally having as substitutes radical R3; R3 independently represents a halogen, C1-C6-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy, C1-C4-alkylthio, C1-C4-halogenalkylthio, amino, halogenthio, C1-C3-alkylamino, C2-C6-alkoxycarbonyl, C2-C6-alkylcarbonyl, C2-C6-alkylaminocarbonyl, hydroxyl, C3-C6-trialkylsilyl, or a system of 5- or 6-member saturated or unsaturated rings, or condensed system consisting of 5- and 6-member rings, or condensed system of 6-6-member rings, each system includes from 1 to 3 heteroatoms and each ring can optionally contain as substitutes from 1 to 3 radicals R4; R4 independently represents a halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, halogenthio, amino, C1-C6-alkylamino, C2-C6-dialkylamino, C2-C6-alkoxycarbonyl, C1-C6-alkylsulphonyl or C2-C6-alkylcarbonyl, nitro, hydroxyl or cyano; R5 represents H, C1-C6-alkyl, C1-C6-alkoxy, phenyl or benzyl, wherein each phenyl or benzyl can optionally contain as substitutes from 1 to 3 radicals R4; R6 represents H, C1-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, C1-C6-haloalkyl, C1-C6-alkoxyalkyl, C2-C6-alkylcarbonyl, phenyl or benzyl, wherein each phenyl or benzyl can optionally contain as substitutes from 1 to 3 radicals R4, or a system of 5- or 6-member saturated or unsaturated rings, or condensed system consisting of 5- and 6-member rings, or condensed system of 6-6-member rings, each system includes from 1 to 3 heteroatoms and each ring can optionally contain as substitutes from 1 to 3 radicals R4, biphenyl or naphthyl, optionally having as substitutes from 1 to 3 radicals R4; R7 represents H, C1-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, C1-C6-haloalkyl, C1-C6-alkoxyalkyl, phenyl or benzyl, wherein each phenyl or benzyl can optionally contain as substitutes from 1 to 3 radicals R4, or a system of 5- or 6-member saturated or unsaturated rings, or condensed system consisting of 5- and 6-member rings, or condensed system of 6-6-member rings, each system includes from 1 to 3 heteroatoms and each ring can optionally contain as substitutes from 1 to 3 radicals R4, biphenyl or naphthyl, optionally having as substitutes from 1 to 3 radicals R4; R8 represents H, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxyalkyl, C2-C6-alkylcarbonyl, phenyl or benzyl, wherein each phenyl or benzyl can optionally contain as substitutes from 1 to 3 radicals R4, or a system of 5- or 6-member saturated or unsaturated rings, or condensed system consisting of 5- and 6-member rings, or condensed system of 6-6-member rings, each system includes from 1 to 3 heteroatoms and each ring can optionally contain as substitutes from 1 to 3 radicals R4, biphenyl or naphthyl, optionally having as substitutes from 1 to 3 radicals R4; and R9 represents H, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxyalkyl, C2-C6-alkylcarbonyl, or benzyl, wherein benzyl can optionally contain as substitutes from 1 to 3 radicals R4; alternatively, R8 and R9 can together form a 5- or 6-member saturated or unsaturated ring containing from 1 to 3 heteroatoms, each ring can optionally contain as substitutes from 1 to 3 radicals R4.EFFECT: higher efficiency of controlling plant fungal diseases.17 cl, 2 tbl, 5 ex
ethod for donor cornea processing with double-sided uv crosslinking for keratoprosthetics of complicated vascular leucomas of category 4-5 // 2613442
FIELD: medicine.SUBSTANCE: donor cornea is placed in a preserving environment for 1 hour. Then the donor cornea is moved into a sterile container and treated with ultraviolet light from one side of the cornea with a wavelength of 365 nm, power of 3 mW/sq. cm. Instillation of 1 drop of 0.1% riboflavin solution (first processing on cornea is performed very 5 minutes. After processing, the donor cornea is treated with ultraviolet light from the opposite side similarly to the first treatment. The preserving environment contains riboflavin mononucleotide, dextran, glutathione, sodium chloride and purified distilled water, in the following ratio, wt %: riboflavin mononucleotide - 0.1, dextran - 10.0, glutathione - 0.09, sodium chloride - 0. 9, purified distilled water - the rest.EFFECT: obtaining of donor cornea with increased biochemical, biomechanical and strength properties, thereby reducing the risk of cornea necrosis.2 cl, 1 ex
Bacteriophages production method // 2613423
FIELD: biotechnology.SUBSTANCE: method comprises culturing bacterial cells of host strain in the absence of extraneous microflora, phage lysate preparation and purification by precipitation and/or filtration. After 30-120 minutes after culturing initiation, at the optimum growth temperature for the culture of rapidly growing host strain, every 30-60 minutes, smears are made from the host strain culture from the surface of solid nutrient medium or from a liquid culture medium. The smears are stained with a solution of acridine orange in the final concentration of 0.001% to 0.02% or acridine yellow solution to the final concentration of 0.01% to 0.2%. The stained smear is microscoped in fluorescence microscope. Time is set for inoculating the mother bacteriophage at achievement in the stained smear of not less than 50% in relation to the total host strain cells proportion of orange acridine stained cells, fluorescing with orange or red shades, or the proportion of yellow acridine stained cells fluorescing with yellow or orange shades, at achevement of less than 10% in relation to the total host strain cells proportion of cells with non-uniform fluorescence that is paired pole adjoining cells in the form of rods with irregular or spherical cytoplasm fluorescent and spherical or ellipsoidal cells with slightly fluorescenting central section. Then mother bacteriophage is inoculated.EFFECT: stability of achieving high bacteriophage titer upon phage lysate production in a changing nutritive medium formulations, and increase in the range of variations of the indicator values of the host strain and bacteriophage culturing.11 ex

Antibody for blys // 2613422
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. The antibody for BLyS is stated. The invention also relates to the DNA molecule encoding the said antibody, the expression vector and the host cell to produce the said antibody. It is also proposed to use BLyS antibodies in a pharmaceutical composition and in the method for prevention and/or treatment of diseases caused by excessive proliferation of B-cells, such as systemic lupus erythematosus. The invention allows binding to BLyS with high affinity and inhibition of binding to its receptor with high BR3 specificity.EFFECT: invention adds a new BLyS antibody concept to biochemistry with a proposal to use the antibody for prevention and/or treatment of diseases caused by excessive proliferation of B-cells.15 cl, 10 dwg, 4 tbl, 10 ex
 
2550808.
Up!